These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 12883235

  • 1. "Lack of clinically significant interference by spironolactone with the Axsym Digoxin II assay" only applies to low-dose therapy with spironolactone.
    Steimer W.
    Ther Drug Monit; 2003 Aug; 25(4):484-5. PubMed ID: 12883235
    [No Abstract] [Full Text] [Related]

  • 2. Digoxin assays: frequent, substantial, and potentially dangerous interference by spironolactone, canrenone, and other steroids.
    Steimer W, Müller C, Eber B.
    Clin Chem; 2002 Mar; 48(3):507-16. PubMed ID: 11861441
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A new turbidometric digoxin immunoassay on the ADVIA 1650 analyzer is free from interference by spironolactone, potassium canrenoate, and their common metabolite canrenone.
    Datta P, Dasgupta A.
    Ther Drug Monit; 2003 Aug; 25(4):478-82. PubMed ID: 12883233
    [Abstract] [Full Text] [Related]

  • 6. Bidirectional (positive/negative) interference of spironolactone, canrenone, and potassium canrenoate on serum digoxin measurement: elimination of interference by measuring free digoxin or using a chemiluminescent assay for digoxin.
    Dasgupta A, Saffer H, Wells A, Datta P.
    J Clin Lab Anal; 2002 Aug; 16(4):172-7. PubMed ID: 12112389
    [Abstract] [Full Text] [Related]

  • 7. Interference between eplerenone and digoxin in fluorescence polarization immunoassay, microparticle enzyme immunoassay, and affinity column-mediated immunoassay.
    Yamada T, Suzuki K, Iguchi K, Kanada Y, Kato R, Ijiri Y, Nishihara M, Murakami S, Hayashi T, Tamai H, Tanaka K.
    Ther Drug Monit; 2010 Dec; 32(6):774-7. PubMed ID: 20625353
    [Abstract] [Full Text] [Related]

  • 8. Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.
    Dasgupta A, Tso G, Wells A.
    Ther Drug Monit; 2008 Dec; 30(6):744-7. PubMed ID: 18824952
    [Abstract] [Full Text] [Related]

  • 9. Intoxication due to negative canrenone interference in digoxin drug monitoring.
    Steimer W, Müller C, Eber B, Emmanuilidis K.
    Lancet; 1999 Oct 02; 354(9185):1176-7. PubMed ID: 10513714
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common metabolite canrenone.
    DeFrance A, Armbruster D, Petty D, Cooper KC, Dasgupta A.
    Ther Drug Monit; 2011 Feb 02; 33(1):128-31. PubMed ID: 21079546
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Digoxin bioequivalence study: determination in human plasma by microparticle enzyme immunoassay.
    Borges NC, Guermani A, Mazucheli JA, Mendes GD, Moreno RA.
    Int J Clin Pharmacol Ther; 2007 Jun 02; 45(6):366-72. PubMed ID: 17595894
    [Abstract] [Full Text] [Related]

  • 15. Assessment of the immunoreactivity of digoxin metabolites and the cross-reactivity with digoxin-like immunoreactive factors in the Roche-TDM ONLINE digoxin assay.
    Bonagura E, Law T, Rifai N.
    Ther Drug Monit; 1995 Oct 02; 17(5):532-7. PubMed ID: 8585119
    [Abstract] [Full Text] [Related]

  • 16. Comparison of microparticle enzyme and fluorescence polarization immunoassays in pediatric patients not receiving digoxin.
    Chicella M, Branim B, Lee KR, Phelps SJ.
    Ther Drug Monit; 1998 Jun 02; 20(3):347-51. PubMed ID: 9631935
    [Abstract] [Full Text] [Related]

  • 17. Spironolactone-associated digoxin radioimmunoassay interference.
    Silber B, Sheiner LB, Powers JL, Winter ME, Sadée W.
    Clin Chem; 1979 Jan 02; 25(1):48-50. PubMed ID: 761378
    [Abstract] [Full Text] [Related]

  • 18. Negligible interference by spironolactone and prednisone in digoxin radioimmunoassay.
    Ravel R.
    Clin Chem; 1975 Nov 02; 21(12):1801-3. PubMed ID: 1183001
    [Abstract] [Full Text] [Related]

  • 19. Unexpected suppression of total digoxin concentrations by cross-reactants in the microparticle enzyme immunoassay: elimination of interference by monitoring free digoxin concentration.
    Dasgupta A, Scott J.
    Am J Clin Pathol; 1998 Jul 02; 110(1):78-82. PubMed ID: 9661925
    [Abstract] [Full Text] [Related]

  • 20. Spironolactone an important addition to heart-failure treatment, study shows.
    Miller JL.
    Am J Health Syst Pharm; 1999 Sep 01; 56(17):1695. PubMed ID: 10512491
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.